BioCentury
ARTICLE | Company News

Elan and Biogen to develop Antegren

August 17, 2000 7:00 AM UTC

ELN and BGEN signed a global, exclusive deal to develop, manufacture and commercialize ELN's Antegren natalizumab, a humanized monoclonal antibody in Phase II testing to treat multiple sclerosis and C...